Shingles Vaccines Linked to Reduced Risk of Various Common Heart Issues

Vaccination against shingles, also known as herpes zoster, not only prevents this painful infection but also lowers the chance of cardiovascular issues.

A recent observational study involving over 1 million participants has revealed that individuals who receive the shingles vaccine Zostavax have a 26% reduced risk of developing heart disease, heart attacks, or heart failure compared to those who are unvaccinated.

“Shingles is known to cause inflammation in blood vessels,” notes a researcher. “Thus, by preventing the infection, vaccines could potentially reduce the risk of cardiovascular diseases.”

Shingles manifests when the varicella-zoster virus, which causes chickenpox, reactivates after lying dormant in the body. This reactivation can happen due to factors like stress or prolonged chemotherapy, leading to painful rashes.

While cardiovascular complications are not commonly highlighted, research has shown a link between shingles and increased risks for conditions such as stroke and heart attack, especially within the first year post-infection, with stroke risk rising by approximately 30% and heart attack risk by 10%.

To investigate whether vaccinations mitigate these risks, Lee and colleagues analyzed data from 1,271,922 individuals over 50, gathered by the South Korean National Health Registry Bureau from 2012 to 2024. They assessed who received the live vaccine and compared it with the later onset of 18 cardiovascular diseases, including heart failure, stroke, and arrhythmias, while also considering various health-related factors like age, gender, and lifestyle.

Throughout a six-year average follow-up period, the study found that the risk of cardiovascular events post-vaccination was 23% lower than in unvaccinated individuals.

The reduction was more pronounced in men, with a 27% lower risk compared to a 20% decrease in women. Among those under 60, there was a 27% reduction in risk, while in older populations, it was 16%. Rural residents showed a 25% risk reduction versus 20% in urban settings, and low-income groups had a 26% decrease, while higher earners experienced a 20% reduction. The data also indicated that risk reduction decreased as BMI increased.

For specific cardiovascular incidents, vaccinated people were found to be 26% less likely to experience a stroke, heart attack, or heart failure, and 26% less likely to die from heart disease. Additionally, the risk of coronary artery disease was reduced by 22%.

The benefits were most significant in the two to three years following vaccination, gradually tapering off over the subsequent five years.

The findings support the notion that shingles vaccination “enhances our confidence” in its capability to lower cardiovascular risk by decreasing vascular inflammation potentially triggered by the shingles virus, states Galen Faulke from Pennsylvania State University.

“Zoster itself has a notably high incidence of pain and postherpetic neuralgia, which can be extremely distressing,” he adds. “However, healthcare systems globally can significantly reduce cardiovascular ailments by advocating the use of cost-effective shingles vaccines.”

While further research is necessary, scientists theorize that the vaccine may indirectly contribute to lowering cardiovascular risks associated with shingles.

Initially, the focus was on Zostavax, which uses viral proteins, but more attention is now directed towards Shingrix.

“That’s why it is more effective at preventing shingles. I believe recombinant vaccines could offer even stronger cardiovascular protection,” Lee explains.

Despite the study design not establishing causality as in randomized trials, researchers can identify risk correlations across a large population. Such extensive data can reveal risk patterns that clinical trials might overlook, Lee explains.